The Food Allergy Diagnosis Treatment Market Size was valued at USD 1.6 Billion in 2023 and is projected to grow from USD 1.72 Billion in 2024 to USD 3.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.60% during the forecast period (2024-2032). Technical developments and growth in research and development initiatives aimed at developing more effective pharmaceuticals are the key market drivers contributing to market growth and expansion.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The rising prevalence of food allergy drives Market CAGR for food allergy diagnosis treatment. Several reasons will contribute to the expansion of the market in the coming years. Among them are, with novel technologies being invented virtually every day, these advances will likely drive growth and increase significantly throughout the predicted period. Another major motivating reason has been a rise in the incidence of food allergies. The market will likely flourish throughout the forecast period with an increase in such situations. The key issue limiting the growth of the allergy testing market is the expensive nature of treating food allergies.
With the rapid growth in the number of patients, it is critical to consider the time and expense involved with food allergy therapy. According to estimates, around 15 million people in the United States will suffer from these allergies by 2021. Furthermore, sophisticated diagnostic procedures are in high demand due to a rise in instances. Applications, foodstuff detectors, and other small devices have been developed for such people to warn them if they attempt to eat anything that could worsen their health conditions. Companies involved in the production of these kinds of gadgets have been working hard to develop new equipment at a rapid rate.
Additionally, the advent of the COVID-19 pandemic triggered a shift in the lives of every individual and organization. Repeated lockdowns and the virus's terror have rendered the situation even more precarious. However, there must be a means of guaranteeing that economic conditions are restored and that no one suffers financially. The major players in the market and the initiatives they have been pursuing have brought them to where they are now. Furthermore, their primary focus is the costs incurred while producing food allergy diagnosis equipment. They aim to ensure that such devices are affordable to the general public.
For instance, the American Academy of Pediatrics shows that 5.6 million kids in the United States have food allergies, with around 40% having multiple allergies. It impacts approximately 6%-8% of children under the age of three and approximately 3% of adults. The rising prevalence of allergy diseases in pediatric and adult populations increases the need for cost-effective and cutting-edge therapies. Thus, it is anticipated that demand for Food Allergy Diagnosis Treatment will increase throughout the projected timeframe due to the rising prevalence of food allergy. Thus, driving the Food Allergy Diagnosis Treatment market revenue.
The Food Allergy Diagnosis Treatment market segmentation, based on Food Sources, includes Eggs, milk, peanuts, seafood, and tree nuts. Peanuts category dominated the market, accounting for 46% of market revenue (USD 0.7 Billion) in 2022. The rising frequency of peanut allergies is driving the category market. In addition, research is ongoing to produce specific AIT that can aid in allergen neutralization in shorter periods with fewer negative effects.
The Food Allergy Diagnosis Treatment market segmentation, based on diagnosis, includes primary & secondary. The primary category generated the highest market revenue of about 69% (USD 1.1 billion) in 2023. The many medical tools and testing kits used to identify and treat food allergies fall under this category.
Figure 1 Food Allergy Diagnosis Treatment Market, by diagnosis, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Food Allergy Diagnosis Treatment market segmentation, based on treatment, includes antihistamines and adrenalin. The Antihistamines segment dominated the market, accounting for 76% of market revenue (USD 1.2 Billion) in 2022. Trials are undergoing research and development to find proven techniques for maximizing benefits while minimizing possible damage.
The Food Allergy Diagnosis Treatment market segmentation, based on End-Users, includes hospitals & clinics and diagnostic centers. The hospital & clinics segment dominated the market, accounting for 55% of market revenue (USD 0.9 Billion) in 2022. The existence of established medical facilities and experienced personnel contributes to this category.
By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Food Allergy Diagnosis Treatment market area will dominate this market during the projected timeframe because of government measures, a spike in anaphylaxis instances, and new technical breakthroughs that will boost the market growth in the North American region.
Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Food Allergy Diagnosis Treatment Market Share by Region 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe region’s Food Allergy Diagnosis Treatment market accounts for the second-highest market share due to increasing knowledge about the numerous therapies available for allergies to foods is also driving demand in this area. Further, the German Food Allergy Diagnosis Treatment market holds the largest market share, and the UK Food Allergy Diagnosis Treatment market is expected to grow and expand significantly in the European region during the projected timeframe.
The Asia-Pacific Food Allergy Diagnosis Treatment Market is expected to grow quickly during the projected timeframe. A rise in the number of food allergies, particularly peanut allergies. This is mostly due to variables such as modernization and lifestyle changes. Furthermore, the region's expanding population is fueling the market in the area. Moreover, China’s Food Allergy Diagnosis Treatment market dominates the market share, and the Indian Food Allergy Diagnosis Treatment market is expected to expand and grow steadily in the Asia-Pacific region during the projected timeframe.
Food Allergy Diagnosis Treatment Key Market Players & Competitive Insights
Leading market players invested heavily in research and Development (R&D) to scale up their manufacturing units and develop technologically advanced solutions, which will help the Food Allergy Diagnosis Treatment market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with significant market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Food Allergy Diagnosis Treatment industry must offer cost-effective and sustainable options to survive in a highly fragmented and dynamic market climate.
Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the critical business strategies organizations use in the Food Allergy Diagnosis Treatment industry to benefit customers and capture untapped market share and revenue. The Food Allergy Diagnosis Treatment industry has recently offered significant advantages to the Healthcare industry. Moreover, more industry participants are utilizing and adopting cutting-edge Technology has grown substantially.
Major players in the Food Allergy Diagnosis Treatment market, including SGS S.A. (Switzerland), Microbac Laboratories, Inc. (US), Intertek Group PLC (UK), AsureQuality Limited (New Zealand), TÜV SÜD AG (Singapore), Mérieux NutriSciences Corporation (US), Eurofins Scientific SE (Luxembourg) and ALS Limited (Australia) are attempting to expand market share and demand by investing in R&D operations to produce sustainable and affordable solutions.
Minaris Medical America collaborates with specialists, labs, and dealers worldwide to bring the newest in vitro allergy evaluation technologies to the medical profession. The business possesses many patents on in vitro testing for allergy technologies and continues to lead the way in the industry. In 2021, Minaris Medical America replaced Hitachi Chemical Diagnostics. Hitachi intends to increase its worldwide position and grow commercially in in-vitro diagnosis by combining healthcare group companies under Minaris Medical. Showa Denko Materials owns both firms.
PerkinElmer is an American multinational firm created in 1937 focusing on precision optics. It helps scientists, researchers, and physicians tackle some of the most pressing scientific and healthcare concerns. They agreed to sign a deal to buy immunodiagnostic systems holding in 2021. It will be able to bolster its standing in the IDS industry due to the purchase. It would be part of EUROIMMUN medizinisch, a firm that provides allergy products and treatments.
Key Companies in the Food Allergy Diagnosis Treatment market include
Food Allergy Diagnosis Treatment Industry Developments
February 2024: The FDA granted approval to Xolair (omalizumab) as the sole medication capable of diminishing allergic reactions to various food items in both youngsters and adults afflicted with food allergies. Xolair is a monoclonal antibody that specifically attaches to immunoglobulin E (IgE), the antibody responsible for initiating allergic responses. It is designed for repetitive utilization in order to mitigate the likelihood of allergic responses, however it is not authorized for immediate intervention in cases of allergic reactions, such as anaphylaxis.
May 2023: Metropolis Healthcare Limited unveiled a cutting-edge testing platform in May 2023 that utilizes Component Resolved Diagnostics (CRD) to aid in the diagnosis of different types of allergies among the people of India. The fourth-generation allergy testing technology employs artificial intelligence (AI) to aid physicians in making informed clinical decisions and offers valuable insights for selecting and optimizing the treatment plan for an individual's allergic condition. This molecular component-based allergy diagnostic test enables the mapping of allergen sensitization in patients at the protein level, facilitating the improved identification and characterization of the particular components that cause allergic reactions. The test, utilizing a nanotechnology-based Multiplex system with molecular components, can accurately identify particular IgE antibodies against 295 different allergens. It achieves this by a straightforward blood test and delivers results for 158 food allergens, 127 respiratory allergens, and 10 contact allergens.
2021:Minaris Medical America has replaced Hitachi Chemical Diagnostics. Hitachi intends to increase its worldwide position and grow commercially in in-vitro diagnosis by combining healthcare group companies under Minaris Medical. Showa Denko Materials owns both firms.
2021:PerkinElmer agreed to sign a deal to buy immunodiagnostic systems holding in 2021. PerkinElmer will be able to bolster its standing in the IDS industry due to the purchase. It would be part of EUROIMMUN medizinisch, a firm that provides allergy products and treatments.
Regarding technology improvements, the food allergy evaluation and therapy industry has seen considerable expansion. So far, the idea has been fantastic, from the applications that identify allergenic materials in the product to the large machine that removes the pollutants.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.6 Billion |
| Market Size 2024 | USD 1.72 Billion |
| Market Size 2032 | USD 3.09 Billion |
| Compound Annual Growth Rate (CAGR) | 7.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Food Source, Diagnosis, Treatment, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | SGS S.A. (Switzerland), Microbac Laboratories, Inc. (US), Intertek Group PLC (UK), AsureQuality Limited (New Zealand), TÜV SÜD AG (Singapore), Mérieux NutriSciences Corporation (US), Eurofins Scientific SE (Luxembourg) and ALS Limited (Australia) |
| Key Market Opportunities | Food allergies are becoming more common. |
| Key Market Dynamics | Some of the market's drivers include technical developments and growth in the amount of research and development initiatives aimed at developing more effective pharmaceuticals. |
Food Allergy Diagnosis Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Food Allergy Diagnosis Treatment market size was valued at USD 1.6 Billion in 2023.
The market is projected to grow at a CAGR of 7.60% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are SGS S.A. (Switzerland), Microbac Laboratories, Inc. (US), Intertek Group PLC (UK), AsureQuality Limited (New Zealand), TÜV SÜD AG (Singapore), Mérieux NutriSciences Corporation (US), Eurofins Scientific SE (Luxembourg) and ALS Limited (Australia).
The Peanuts category dominated the market in 2022.
The Primary has the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
| FEATURES | LICENCE TYPE | ||
|---|---|---|---|
| Single User | Multiuser Licence | Enterprise User | |
| Price | $ 4,950 | $ 5,950 | $ 7,250 |
| Maximum User Access Limit | 1 User | Upto 10 Users | Unrestricted Access Throughout The Organization. |
| Free Customization |  |
|
|
| Direct access to the Analyst | |
|
|
| Deliverable Format | |
|
|
 |
|
|
|
| Platform Access | |
|
|
| Discount on Your Next Purchase | 10% | 15% | 10% |
| Printable Versions | |
|
|
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
